Q3 2026
Released Nov 10, 2026, after the close
10-Q filed Nov 12, 2026, 43 days after period end · 0001628280-26-073392
What the release said
On November 10, 2026, Prime Medicine, Inc. (the “Company”) announced that the preliminary unaudited estimates of its cash, cash equivalents, and short-term investments were approximately $61.2 million as of September 30, 2026, excluding its restricted cash of approximately $13.7 million.
Prime Medicine announced preliminary unaudited estimates of approximately $61.2 million in cash, cash equivalents, and short-term investments as of September 30, 2026, excluding restricted cash of approximately $13.7 million.¶1
The estimates are based on preliminary unaudited information, the quarter-end financial close is not yet complete, and PricewaterhouseCoopers LLP has not audited or reviewed them.¶1¶2
Complete results as of September 30, 2026 will be included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.¶2
On November 10, 2026, the Company posted an updated corporate presentation to its website and attached it as Exhibit 99.1 to the Form 8-K.¶3
- Preliminary unaudited cash, cash equivalents, and short-term investments
- $61.2 million As of September 30, 2026, excluding restricted cash¶1
- Restricted cash
- $13.7 million Excluded from the $61.2 million figure; as of September 30, 2026¶1
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $4.21M | $1.23M | $209.00K | $0.00 |
| Net Income | -$39.04M | -$50.58M | -$52.52M | -$50.71M |
| EPS Diluted | -$0.22 | -$0.32 | -$0.44 | -$0.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR